IN

India

IN

South Asia

Regulatory Overview

India is regulated by the Central Drugs Standard Control Organization (CDSCO). The country has 3 documented regulatory pathways for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

Central Drugs Standard Control Organization (CDSCO)

Regulatory Pathways (3)

Rule 96 of NDCT Rules 2019 allows compassionate use of new drugs for patients with serious or life-threatening diseases who are not eligible for clinical trials and have no other treatment options.

Application Form: CDSCO CU Application
Legal Basis: NDCT Rules 2019 Rule 96
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: CDSCO New Drugs and Clinical Trials Rules 2019

Under India's New Drugs and Clinical Trials Rules 2019, a named patient can import unapproved drugs on Form 12B with CDSCO approval for personal use to treat a specific disease.

Application Form: Form 12B
Legal Basis: NDCT Rules 2019, Rule 101
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: CDSCO GSR 354(E) 2019

Under India's New Drugs and Clinical Trials Rules 2019, a named patient can import unapproved drugs...

Application Form: Form 12B
Legal Basis: Regulated
Eligibility: Patient must have no alternative licensed treatment available in India.
Reference: CDSCO GSR 354(E)

Drugs Available (67)

DrugAccess RouteStatusLead Time
cytarabine———
furosemide———
Sucralfate———
propranolol———
tamoxifen citrate———
atropine sulfate———
metoprolol———
carbamazepine———
mycophenolate mofetil———
diethylcarbamazine———
minoxidil———
Artificial tears———
Baclofen———
phacoemulsification surgery———
ascorbic acid———
Digoxin———
physical therapy and orthotic management———
oxybutynin———
Valproic Acid———
Immunoglobulin———
Phenytoin———
Metronidazole———
sirolimus———
temozolomide———
Pyridoxine———
Angiotensin-Converting Enzyme Inhibitors (Enalapril)———
ivermectin———
azathioprine———
sunscreen (broad spectrum SPF 50+)———
L-carnitine———
rituximab———
allopurinol———
Topical corticosteroids———
Erythromycin———
coenzyme Q10———
tacrolimus ophthalmic———
ImigluceraseRegisteredCommercially available5 days
diacerein———
Methotrexate———
calcitriol———
doxorubicin———
Pyridostigmine———
Levetiracetam———
prednisone———
salicylic acid———
cochlear implant———
Pyridostigmine Bromide———
Bleomycin———
pregabalin———
riboflavin———
Diosmin———
bevacizumab———
Biotin———
deferasirox———
RisdiplamNamed PatientAvailable via NPP7 days
urea———
Levodopa/Carbidopa———
cyanocobalamin———
Hypertonic saline———
emollients with keratolytics———
surgical repair———
Tamoxifen———
Artificial tears (Hypromellose)———
NusinersenNamed PatientAvailable via NPP7 days
Hematopoietic stem cell transplantation———
Timolol maleate———
Amnioreduction———
IN
India
ISO CodeIN
RegionSouth Asia
Regulatory AuthorityCentral Drugs Standard Control Organization (CDSCO)
Pathways3 documented
Drugs Available67 drug(s)